26 results
8-K
EX-99.1
RGNX
Regenxbio Inc
27 Feb 24
REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
4:10pm
in neurodevelopmental skill acquisition up to four years and discontinued intravenous enzyme therapy.
NAVĀ® TECHNOLOGY PLATFORM LICENSEE PROGRAM HIGHLIGHTS
8-K
EX-99.1
RGNX
Regenxbio Inc
3 May 23
REGENXBIO Reports First Quarter 2023 Financial Results and Recent Operational Highlights
4:11pm
, improvements in neurodevelopmental and daily activity skill acquisition were observed up to three years after RGX-121 administration.
A Phase I/II trial
8-K
EX-99.1
5ecwbz4fkr0w8fx
4 May 22
REGENXBIO Reports First Quarter 2022 Financial Results and Recent Operational Highlights
4:12pm
8-K
EX-99.2
cwwhvwbptg2h6wjrh
9 Feb 22
RGX-121, a one-time gene therapy for MPS II, continues to be well-tolerated with no drug-related SAEs across three dose levels
11:41am
8-K
EX-99.1
40zrv
9 Feb 22
RGX-121, a one-time gene therapy for MPS II, continues to be well-tolerated with no drug-related SAEs across three dose levels
11:41am